All the Active Ingredient Drugs
Topoisomerase I Inhibitor. Topotecan HCl 0.25 mg, 1 mg. HARD CAPS: 10 x 0.25 mg, 1 mg. See lit.
Tmt. pts with relapsed small cell lung
cancer (SCLC) when re-tmt. with first-line
regimen not approp.
C/I: Severe hypersens., pregn., lact.,
severe bone marrow depress. prior to
start. 1st course (baseline neutrophils
less than 1.5 x 10^9/L and/or placelet
count less than 100 x 10^9/L.
Topoisomerase I Inhibitor. Topotecan HCl 4 mg. VIAL (for infusion): 1. Dose must adjust.
accord. to indication, blood counts and
pt’s medical condit. See it.
Metastat. carcinoma ovary where 1st -line
or subsequent ther. failed, small cell lung
cancer sens. dis. aft. fail. first line chemo.
In comb. with cisplatin: Stage IV-B recur./
persist. carcinoma cervix not amenable to
curative tmt. with surg. and/or radiat.
ther.
C/I: Hypersens., lact., pts. already have
severe bone marrow depress. prior to
starting 1st course, as evidenced by
baseline neutrophils < 1.5 x 109/l and/
or a platelet count of <100 x 109/l.
